ESMO 2019 | FORWARD I: mirvetuximab soravtansine vs chemo in platinum-resistant ovarian cancer

Kathleen Moore

Kathleen Moore, MD, Stephenson Cancer Center, Oklahoma City, OK, talks about the FORWARD I Phase III study of mirvetuximab soravtansine (NCT02631876), a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), versus chemotherapy in patients with platinum-resistant ovarian cancer (PROC). This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

Share this video  
Similar topics